More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$9.63B
EPS
37.91
P/E ratio
44.7
Price to sales
3.78
Dividend yield
--
Beta
1.06162
Previous close
$360.26
Today's open
$359.39
Day's range
$356.50 - $361.69
52 week range
$236.73 - $396.23
show more
CEO
Norman Schwartz
Employees
7450
Headquarters
Hercules, CA
Exchange
New York Stock Exchange
Shares outstanding
26892945
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Bio-Rad Laboratories, Inc. (BIO) Presents at 2026 UBS Global Healthcare Conference Transcript
Bio-Rad Laboratories, Inc. ( BIO ) 2026 UBS Global Healthcare Conference November 10, 2026 8:00 AM EST Company Participants Roop Lakkaraju - Executive VP & CFO Conference Call Participants Douglas Schenkel - UBS Investment Bank, Research Division Presentation Douglas Schenkel UBS Investment Bank, Research Division Welcome Roop Lakkaraju, EVP and Chief Financial Officer of Bio-Rad. Roop, thank you for being here this morning.
Seeking Alpha • Nov 10, 2026

Why Bio-Rad (BIO) International Revenue Trends Deserve Your Attention
Examine the evolution of Bio-Rad's (BIO) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.
Zacks Investment Research • Nov 9, 2026

What Bio-Rad Laboratories (BIO) Said on Its Q3 Earnings Call
Bio-Rad Laboratories NYSE: BIO reported modest third-quarter revenue growth, its first currency-neutral increase of 2026, as gains in clinical diagnostics and digital PCR instruments helped offset weakness in parts of its life sciences business.
MarketBeat • Nov 5, 2026

Bio-Rad Laboratories, Inc. (BIO) Q3 2026 Earnings Call Transcript
Bio-Rad Laboratories, Inc. (BIO) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 5, 2026

Bio-Rad Reports Third-Quarter 2026 Financial Results
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the third quarter ended September 30, 2026. Norman Schwartz, Bio-Rad's Chief Executive Officer, stated: “Our third-quarter results reflect the steady progress we have been driving. We returned to currency-neutral revenue growth, led by Clinical Diagnostics and strong demand for our Droplet Digital™.
Business Wire • Nov 4, 2026

Bio-Rad Laboratories (BIO) Q3 Earnings Top Estimates
Bio-Rad Laboratories (BIO) came out with quarterly earnings of $2.65 per share, beating the Zacks Consensus Estimate of $2.61 per share. This compares to earnings of $2.26 per share a year ago.
Zacks Investment Research • Nov 4, 2026

Bio-Rad to Participate in Fireside Chat During UBS Global Healthcare Conference
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Financial Officer, Roop K. Lakkaraju, will participate in a fireside chat event during the UBS Global Healthcare Conference on Tuesday, November 10, 2026, at 8:00 AM Eastern Time. A live webcast and subsequent replay of the event will be available in the Investor Relations section of Bio-Rad's website at i.
Business Wire • Oct 29, 2026

Ariel Appreciation Fund Q3 2026 Scorecard: Buys, Sells, And Standouts
Charles River Laboratories advanced during the quarter following a strong earnings report and an increase to full-year guidance. We exited the NCLH position during the quarter and redeployed proceeds into Royal Caribbean Group. Middleby completed the spin-off of Midera Food Processing, announced plans to exit its underperforming business, and continued buying back shares.
Seeking Alpha • Oct 28, 2026

Ariel Fund Q3 2026 Leaders And Laggards
ZBRA's revenue growth accelerated across end markets and geographies, while margins and earnings exceeded expectations. CRL's results reflected improving demand across biopharma and biotechnology customers. Bio-Rad's shares also benefited from the announcement of a broad restructuring program designed to streamline operations and enhance profitability.
Seeking Alpha • Oct 26, 2026

Bio-Rad to Report Third-Quarter 2026 Financial Results on Wednesday, November 4, 2026
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the third quarter of 2026 on Wednesday, November 4, 2026, following the close of the market. Management will discuss these results in a conference call scheduled for 2:00 PM Pacific Time (5:00 PM Eastern Time) that day.To participate, dial (800) 715-9871 within the U.S. or (646) 307-1963 outside the.
Business Wire • Oct 14, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Bio-Rad Laboratories Inc. Class A commission-free¹. Build wealth for the long term using automated trading and transfers.